Table of Content

Archive

Autumn 2012, Vol. 20 No. 3

Hong Kong J. Dermatol. Venereol. (2012) 20, 100-105


Original Article

Survey on symptomatic cutaneous manifestations of Epidermal Growth Factor Receptor Inhibitors (EGFRI) in oncology patients at a regional hospital

在一家地區性醫院的腫瘤患者在接受表皮生長因子受體抑制劑 (EGFRI)後的皮膚表現症狀調查

KH Yeung 楊國鴻, Y Chan 陳湧, SH Lo 魯勝雄, KK Choi 蔡國強, WY Tin 佃穎恩, Y Tung 董煜

Abstract

Epidermal Growth Factor Receptor Inhibitors (EGFRI) is a new group of target therapy for a number of carcinomas. Its use may result in cutaneous manifestations which indicate a better tumour response to that therapy. We conducted a survey on the cutaneous manifestations in symptomatic oncology patients who were on EGFRI. A total of 34 patients were recruited within the 1 year study period. Papulopustular eruption (20.5%) was the most common skin manifestation, followed by pruritus (19.9%) and dry skin (19.2%). The relatively low incidence can be explained by the study design which only symptomatic patients were recruited. Five patients (14.7%) had their treatment withheld due to intolerable cutaneous side effects. Collaboration between clinical oncologist and dermatologist should minimize the cutaneous side effects and enhance the compliance of these patients to this life-prolonging therapy.

表皮生長因子受體抑制劑是用於多種癌症的新類型標靶治療。使用這種治療可能引致各種皮膚副作用,但這也反映該腫瘤對治療有更好的反應。我們進行了一項調查,對於用上了表皮生長因子 受體抑制劑而有皮膚症狀的腫瘤患者進行評估。在一年的研究期間,共招募了34名患者。丘疹膿庖疹(20.5%)是最常見的皮膚症狀,其次為瘙癢(19.9%)和皮膚乾燥(19.2%)。這調查中的 發病率相對較低,是因為這研究只招募了有癥狀的患者。五位病人(14.7%)由於無法忍受皮膚的副作用,他們曾被暫停治療。臨床腫瘤科醫生和皮膚科醫生之間的合作可盡量減少皮膚的副作用, 從而提高患者可持續地使用這種可延長生命的治療。

Keywords: Cutaneous manifestations, EGFRI, Epidermal Growth Factor Receptor Inhibitor

關鍵詞: 皮膚表現,EGFRI,表皮生長因子受體抑制